Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 12/20 | 0.69 |
| ▸ | CYBB | P04839 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302213 | 0.86 | NOX4 (0.53) | NOX4CYP3A4SMN1; SMN2NTRK1NTRK3 | |
| SCHEMBL1303159 | 0.85 | NOX4 (0.52) | NOX4CYP3A4SMN1; SMN2NTRK1NTRK3 | |
| SCHEMBL1302791 | 0.85 | NOX4 (0.59) | NOX4CYBBCYP3A4NOX1SMN1; SMN2 | |
| SCHEMBL1302967 | 0.85 | NOX4 (0.73) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL1302600 | 0.84 | NOX4 (0.54) | NOX4CYBBCYP3A4NOX1F2 | |
| SCHEMBL8499938 | 0.83 | NOX4 (0.51) | NOX4CYBBCYP3A4NOX1SMN1; SMN2 | |
| SCHEMBL1301781 | 0.82 | NOX4 (0.64) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL2214964 | 0.82 | NOX4 (1.00) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL1302410 | 0.81 | NOX4 (0.75) | NOX4CYBBCYP3A4NOX1SMN1; SMN2 | |
| SCHEMBL1303193 | 0.81 | NOX4 (0.54) | NOX4CYBBCYP3A4NOX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | claimed |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2020-09-15 | — | — | US | claimed |
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2018-08-23 | — | — | US | claimed |
| US-9974791-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-05-22 | — | — | US | claimed |
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2015-10-15 | — | — | US | claimed |
| US-9096588-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-08-04 | — | — | US | claimed |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | claimed |
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2020-09-15 | — | — | US | disclosed |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2020-09-15 | — | — | US | disclosed |
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-9974791-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-05-22 | — | — | US | disclosed |
| US-9974791-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-05-22 | — | — | US | disclosed |
| EP-2344492-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | disclosed |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | disclosed |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | disclosed |
| EP-2344492-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010035221-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010035221-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885CYP3A4 157/4885 |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885CYP3A4 157/4885 |
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885CYP3A4 157/4885 |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885CYP3A4 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.